Isoprenoids and protein prenylation: implications in the pathogenesis and therapeutic intervention of Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
The mevalonate-isoprenoid-cholesterol biosynthesis pathway plays a key role in human health and disease. The importance of this pathway is underscored by the discovery that two major isoprenoids, farnesyl and geranylgeranyl pyrophosphate, are required to modify an array of proteins through a process known as protein prenylation, catalyzed by prenyltransferases. The lipophilic prenyl group facilitates the anchoring of proteins in cell membranes, mediating protein-protein interactions and signal transduction. Numerous essential intracellular proteins undergo prenylation, including most members of the small GTPase superfamily as well as heterotrimeric G proteins and nuclear lamins, and are involved in regulating a plethora of cellular processes and functions. Dysregulation of isoprenoids and protein prenylation is implicated in various disorders, including cardiovascular and cerebrovascular diseases, cancers, bone diseases, infectious diseases, progeria, and neurodegenerative diseases including Alzheimer's disease (AD). Therefore, isoprenoids and/or prenyltransferases have emerged as attractive targets for developing therapeutic agents. Here, we provide a general overview of isoprenoid synthesis, the process of protein prenylation and the complexity of prenylated proteins, and pharmacological agents that regulate isoprenoids and protein prenylation. Recent findings that connect isoprenoids/protein prenylation with AD are summarized and potential applications of new prenylomic technologies for uncovering the role of prenylated proteins in the pathogenesis of AD are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439 · cited 2×
“Statins have been successfully used to control plasma cholesterol levels and prevent cardiovascular disease (4S-group 1994; Sacks et al. 1996; Goldstein and Brown 2015).”
MethodNeuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · cited 1×
“In parallel with misfolded aggregates of Ab and hyperphosphorylated tau, emerging evidence indicates that microglia-mediated neuroinflammation plays an important role in AD pathogenesis (Akiyama et al. 2000; Heneka et al. 2015).”
BackgroundA Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Regulation of the mevalonate pathway
Goldstein, J. L., & Brown, M. S. (1990) · Nature · doi:10.1038/343425a0 · Cited by 5,394
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
Brown, M. S., & Goldstein, J. L. (1997) · Cell · doi:10.1016/s0092-8674(00)80213-5 · Cited by 3,834
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 2×
“loid cells 2 (TREM2), an innate immune receptor found in brain microglia, are associated with a significantly increased risk of AD (Guerreiro et al. 2013; Jonsson et al. 2013; Colonna and Wang 2016).”
BackgroundVariant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 2×
“loid cells 2 (TREM2), an innate immune receptor found in brain microglia, are associated with a significantly increased risk of AD (Guerreiro et al. 2013; Jonsson et al. 2013; Colonna and Wang 2016).”
BackgroundPLEIOTROPIC EFFECTS OF STATINS
Liao, J. K., & Laufs, U. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095748 · Cited by 1,994
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943 · cited 1×
“Importantly, all biological functions of Ras occur at the plasma membrane (Simanshu et al. 2017), including interactions with regulatory proteins, downstream effector proteins, and signal transduction.”
BackgroundStructural mechanism for statin inhibition of HMG-CoA reductase
Istvan, E. S., & Deisenhofer, J. (2001) · Science · doi:10.1126/science.1059344 · Cited by 1,644 · cited 1×
“Each of the statins has a characteristic structure that competes with HMG-CoA binding to HMG-CoA reductase (Istvan and Deisenhofer 2001) (Figure 5).”
BackgroundPleiotropic Effects of Statins on the Cardiovascular System
Oesterle, A., Laufs, U., & Liao, J. K. (2017) · Circulation Research · doi:10.1161/circresaha.116.308537 · Cited by 1,247 · cited 3×
“…prenylation in inflammation, numerous studies have reported that statins exert anti-inflammatory activities, and these immunomodulatory properties of statins have been proposed to arise from the regulation of small GTPases (Cordle and Landreth 2005; Liao and Laufs 2009; Oesterle et al. 2017).”
BackgroundRegulation of Small GTPases by GEFs, GAPs, and GDIs
Cherfils, J., & Zeghouf, M. (2013) · Physiological Reviews · doi:10.1152/physrev.00003.2012 · Cited by 1,245
A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins
Goldstein, J. L., & Brown, M. S. (2015) · Cell · doi:10.1016/j.cell.2015.01.036 · Cited by 1,233
The GSK3 hypothesis of Alzheimer’s disease
Hooper, C., Killick, R., & Lovestone, S. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05194.x · Cited by 1,191 · cited 1×
“Notably, GSK-3b is a major kinase driving tau phosphorylation thereby contributing to AD pathogenesis (Hooper et al. 2008).”
BackgroundRole of Pro-Inflammatory Cytokines Released from Microglia in Neurodegenerative Diseases
Smith, J. A., Das, A., Ray, S. K., & Banik, N. L. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.10.004 · Cited by 1,165
Amyloid Precursor Protein Trafficking, Processing, and Function
Thinakaran, G., & Koo, E. H. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r800019200 · Cited by 1,141
Reinsertion or Degradation of AMPA Receptors Determined by Activity-Dependent Endocytic Sorting
Ehlers, M. D. (2000) · Neuron · doi:10.1016/s0896-6273(00)00129-x · Cited by 1,096
Blalock, E. M., Geddes, J. W., Chen, K. C., Porter, N. M., Markesbery, W. R., & Landfield, P. W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308512100 · Cited by 1,025 · cited 1×
“Moreover, microarray correlation analyses in hippocampal samples from AD subjects and control subjects identified upregulation of six out of 10 genes involved in isoprenoid metabolism in AD hippocampal samples (Blalock et al. 2004).”
BackgroundARUK Consortium, Sims, R., GERAD/PERADES, C., van der Lee, S. J., Naj, A. C., Bellenguez, C., Badarinarayan, N., Jakobsdottir, J., Kunkle, B. W., Boland, A., et al. (2017) · Nature Genetics · doi:10.1038/ng.3916 · Cited by 1,012
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975 · cited 1×
“However, chronic exposure to toxic Ab in AD results in the loss of the ability to suppress these immune responses thereby contributing to disease pathology (Wyss-Coray and Rogers 2012).”
BackgroundThe discovery and development of HMG-CoA reductase inhibitors.
Endo, A. (1992) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41379-3 · Cited by 847
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795 · cited 1×
“Two of the major Ras-driven signaling pathways are the MAPK (Raf/MEK/ERK) and PI3K/Akt/ mTOR pathways, which regulate a plethora of key cellular processes and functions under both physiological and pathological conditions (Stephen et al. 2014; Nussinov et al. 2018).”
BackgroundAndersen, O. M., Reiche, J., Schmidt, V., Gotthardt, M., Spoelgen, R., Behlke, J., von Arnim, C. A. F., Breiderhoff, T., Jansen, P., Wu, X., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503689102 · Cited by 655
Targeting protein prenylation for cancer therapy
Berndt, N., Hamilton, A. D., & Sebti, S. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3151 · Cited by 614 · cited 3×
“…the prenyltransferases and developing prenyltransferase inhibitors as potential therapeutic agents for cancers (WinterVann and Casey 2005; Berndt et al. 2011; Brown and CONTACT Ling Li lil@umn.edu Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis,…”
BackgroundCD14 and Toll-Like Receptors 2 and 4 Are Required for Fibrillar Aβ-Stimulated Microglial Activation
Reed-Geaghan, E. G., Savage, J. C., Hise, A. G., & Landreth, G. E. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3158-09.2009 · Cited by 591
Castegna, A., Aksenov, M., Aksenova, M., Thongboonkerd, V., Klein, J. B., Pierce, W. M., Booze, R., Markesbery, W. R., & Butterfield, D. A. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00914-0 · Cited by 581 · cited 1×
“The same proteomic technique led to the identification of UCHL1 as a major target of oxidative damage in AD (Castegna et al. 2002; Choi et al. 2004).”
MethodChoi, J., Levey, A. I., Weintraub, S. T., Rees, H. D., Gearing, M., Chin, L.-S., & Li, L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m314124200 · Cited by 568 · cited 1×
“The same proteomic technique led to the identification of UCHL1 as a major target of oxidative damage in AD (Castegna et al. 2002; Choi et al. 2004).”
MethodSelf-citationOhashi, K., Nagata, K., Maekawa, M., Ishizaki, T., Narumiya, S., & Mizuno, K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.5.3577 · Cited by 533 · cited 1×
“Rho GTPases, including Rac1, Cdc42, and RhoA, regulate neurite outgrowth and spine dynamics through their downstream effectors P21-activated kinases and ROCK (Ohashi et al. 2000; Haditsch et al. 2009; Briz et al. 2015).”
BackgroundSeyfried, N. T., Dammer, E. B., Swarup, V., Nandakumar, D., Duong, D. M., Yin, L., Deng, Q., Nguyen, T., Hales, C. M., Wingo, T., et al. (2017) · Cell Systems · doi:10.1016/j.cels.2016.11.006 · Cited by 477
TREM2, microglia, and neurodegenerative diseases
Yeh, F. L., Hansen, D. V., & Sheng, M. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.03.008 · Cited by 440 · cited 2×
“While the exact role of TREM2 in AD is being actively investigated (Jay et al. 2017; Ulrich et al. 2017; Yeh et al. 2017), it is well established that aggregated Ab leads to microglial activation by interacting with Toll-like receptors (TLRs) (Landreth and Reed-Geaghan 2009; Su et al. 2016).”
BackgroundTLR2 Is a Primary Receptor for Alzheimer’s Amyloid β Peptide To Trigger Neuroinflammatory Activation
Liu, S., Liu, Y., Hao, W., Wolf, L., Kiliaan, A. J., Penke, B., Rübe, C. E., Walter, J., Heneka, M. T., Hartmann, T., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101121 · Cited by 439 · cited 2×
“2009), and induce the release of proinflammatory cytokines such as IL-1b, IL-6, and TNFa upon binding of aggregated Ab (Liu et al. 2012; Smith et al. 2012).”
BackgroundTREM2 in Neurodegenerative Diseases
Jay, T. R., von Saucken, V. E., & Landreth, G. E. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0197-5 · Cited by 427 · cited 2×
“While the exact role of TREM2 in AD is being actively investigated (Jay et al. 2017; Ulrich et al. 2017; Yeh et al. 2017), it is well established that aggregated Ab leads to microglial activation by interacting with Toll-like receptors (TLRs) (Landreth and Reed-Geaghan 2009; Su et al. 2016).”
BackgroundTREM2 variants: new keys to decipher Alzheimer disease pathogenesis
Colonna, M., & Wang, Y. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.7 · Cited by 418 · cited 2×
“loid cells 2 (TREM2), an innate immune receptor found in brain microglia, are associated with a significantly increased risk of AD (Guerreiro et al. 2013; Jonsson et al. 2013; Colonna and Wang 2016).”
BackgroundHaag, M. D. M., Hofman, A., Koudstaal, P. J., Stricker, B. H. C., & Breteler, M. M. B. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.150433 · Cited by 393 · cited 2×
“Several crosssectional, cohort, and case-control studies have found significantly lower incidence and slower progression of AD in statin users (Jick et al. 2000; Wolozin et al. 2000; Haag et al. 2009).”
BackgroundPost-prenylation-processing enzymes as new targets in oncogenesis
Winter-Vann, A. M., & Casey, P. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1612 · Cited by 357
Elucidating the Role of TREM2 in Alzheimer’s Disease
Ulrich, J. D., Ulland, T. K., Colonna, M., & Holtzman, D. M. (2017) · Neuron · doi:10.1016/j.neuron.2017.02.042 · Cited by 325
Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease
Zhao, L., Ma, Q.-L., Calon, F., Harris-White, M. E., Yang, F., Lim, G. P., Morihara, T., Ubeda, O. J., Ambegaokar, S., Hansen, J. E., et al. (2006) · Nature Neuroscience · doi:10.1038/nn1630 · Cited by 317 · cited 2×
“Both hypo- and hyper-activation of these small GTPases and their downstream effectors have been shown to have detrimental effects on synaptic plasticity and cognitive functions, and have been implicated in learning and neurodegenerative disorders (Brambilla et al. 1997; Zhao et al. 2006; Haditsch et al. 2009).”
BackgroundLoss of apolipoprotein E receptor LR11 in Alzheimer disease
Scherzer, C. R., Offe, K., Gearing, M., Rees, H. D., Fang, G., Heilman, C. J., Schaller, C., Bujo, H., Levey, A. I., & Lah, J. J. (2004) · Archives of Neurology · doi:10.1001/archneur.61.8.1200 · Cited by 316 · cited 2×
“2011), which is genetically associated with AD and has been shown to regulate intracellular transport and processing of APP (Scherzer et al. 2004; Andersen et al. 2005; Offe et al. 2006).”
BackgroundControl of synapse development and plasticity by Rho GTPase regulatory proteins
Tolias, K. F., Duman, J. G., & Um, K. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.04.011 · Cited by 261 · cited 1×
“Tight spatiotemporal regulation of Rho GTPase signaling is critical in the neural circuit formation especially during neurodevelopment (Tolias et al. 2011).”
BackgroundStatins and Cognitive Function: A Systematic Review
Richardson, K., Schoen, M., French, B., Umscheid, C. A., Mitchell, M. D., Arnold, S. E., Heidenreich, P. A., Rader, D. J., & deGoma, E. M. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-10-201311190-00007 · Cited by 250
Kirouac, L., Rajic, A. J., Cribbs, D. H., & Padmanabhan, J. (2017) · eneuro · doi:10.1523/eneuro.0149-16.2017 · Cited by 207 · cited 3×
“reported that exposure to Ab oligomers activated GSK-3b and increased p-tau levels in parallel with the elevation of APP hyperphosphorylation at Thr668 through the activation of Ras-ERK in rat neuroblastoma B103 cells expressing sweAPP (Kirouac et al. 2017).”
BackgroundInfluentialDendritic spines provide cognitive resilience against Alzheimer's disease
Boros, B. D., Greathouse, K. M., Gentry, E. G., Curtis, K. A., Birchall, E. L., Gearing, M., & Herskowitz, J. H. (2017) · Annals of Neurology · doi:10.1002/ana.25049 · Cited by 198
Statins Reduce Amyloid-β Production through Inhibition of Protein Isoprenylation
Ostrowski, S. M., Wilkinson, B. L., Golde, T. E., & Landreth, G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702640200 · Cited by 180 · cited 3×
“The notion that statin-induced effects on Ab levels are mediated through protein prenylation is supported by other studies described below, where the treatment duration was longer (24 h) and the level of protein prenylation was measured (Pedrini et al. 2005; Ostrowski et al. 2007).”
BackgroundResultModulation of Statin-Activated Shedding of Alzheimer APP Ectodomain by ROCK
Pedrini, S., Carter, T. L., Prendergast, G., Petanceska, S., Ehrlich, M. E., & Gandy, S. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020018 · Cited by 154 · cited 4×
“The notion that statin-induced effects on Ab levels are mediated through protein prenylation is supported by other studies described below, where the treatment duration was longer (24 h) and the level of protein prenylation was measured (Pedrini et al. 2005; Ostrowski et al. 2007).”
BackgroundResultInfluentialHerskowitz, J. H., Feng, Y., Mattheyses, A. L., Hales, C. M., Higginbotham, L. A., Duong, D. M., Montine, T. J., Troncoso, J. C., Thambisetty, M., Seyfried, N. T., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2508-13.2013 · Cited by 150 · cited 2×
“It was suggested that ROCK1 and ROCK2 might differentially affect Ab production as selective ROCK2 inhibition significantly reduced Ab along with the suppression of BACE1 activity, whereas the depletion of ROCK1 increased Ab levels (Herskowitz et al. 2013).”
BackgroundCavallini, A., Brewerton, S., Bell, A., Sargent, S., Glover, S., Hardy, C., Moore, R., Calley, J., Ramachandran, D., Poidinger, M., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.463984 · Cited by 133 · cited 1×
“Furthermore, a high-throughput cell-based assay identified Ras GTPases as a putative pathway involved in tau phosphorylation (Cavallini et al. 2013).”
BackgroundYe, X., & Carew, T. J. (2010) · Neuron · doi:10.1016/j.neuron.2010.09.013 · Cited by 121
Henderson, B. W., Gentry, E. G., Rush, T., Troncoso, J. C., Thambisetty, M., Montine, T. J., & Herskowitz, J. H. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13688 · Cited by 120 · cited 1×
“Furthermore, a recent study showed that ROCK1 is increased in AD and reduction of ROCK1 or ROCK2 in neurons suppresses Ab production, likely through induction of autophagy by Rho/ROCK signaling to enhance APP protein degradation (Henderson et al. 2016).”
BackgroundVlkolinský, R., Cairns, N., Fountoulakis, M., & Lubec, G. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00218-4 · Cited by 95
Gentry, E. G., Henderson, B. W., Arrant, A. E., Gearing, M., Feng, Y., Riddle, N. C., & Herskowitz, J. H. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.2336-15.2016 · Cited by 90 · cited 1×
“The link between RhoA/ROCK pathway and tauopathy has been further demonstrated in a recent study (Gentry et al. 2016), which showed that ROCK1 and ROCK2 were elevated in the brains of patients with non-AD tauopathies, progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD).”
Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy
Boimel, M., Grigoriadis, N., Lourbopoulos, A., Touloumi, O., Rosenmann, D., Abramsky, O., & Rosenmann, H. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31819ac3cb · Cited by 86 · cited 1×
“In contrast, a later study showed that simvastatin treatment in vivo significantly reduced NFT burdens in a double-mutant tau transgenic mouse model (Boimel et al. 2009).”
ResultInitiative, F. T. A. D. N., Ridge, P. G., Karch, C. M., Hsu, S., Arano, I., Teerlink, C. C., Ebbert, M. T. W., Gonzalez Murcia, J. D., Farnham, J. M., Damato, A. R., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0486-1 · Cited by 83 · cited 3×
“Recent genome-wide association studies (GWASs) and an epigenome-wide association study have identified 30 putative risk susceptibility genes (Lambert 2013; Rosenthal and Kamboh 2014; Ridge et al. 2017; Sims et al. 2017).”
BackgroundInfluentialAlzheimer's disease: An acquired neurodegenerative laminopathy
Frost, B. (2016) · Nucleus · doi:10.1080/19491034.2016.1183859 · Cited by 74 · cited 1×
“Interestingly, a recent study showed that dysfunction of lamin mediates neurodegeneration in AD and suggested that AD could be an acquired neurodegenerative laminopathy (Frost 2016).”
BackgroundPitavastatin decreases tau levels via the inactivation of Rho/ROCK
Hamano, T., Yen, S.-H., Gendron, T., Ko, L.-W., & Kuriyama, M. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.10.020 · Cited by 49
Cited by
Statins: a repurposed drug to fight cancer
Jiang, W., Hu, J.-W., He, X.-R., Jin, W.-L., & He, X.-Y. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02041-2 · Cited by 417
Cholesterol and beyond - The role of the mevalonate pathway in cancer biology
Göbel, A., Rauner, M., Hofbauer, L. C., & Rachner, T. D. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188351 · Cited by 164
Varma, V. R., Büşra Lüleci, H., Oommen, A. M., Varma, S., Blackshear, C. T., Griswold, M. E., An, Y., Roberts, J. A., O’Brien, R., Pletnikova, O., et al. (2021) · npj Aging and Mechanisms of Disease · doi:10.1038/s41514-021-00064-9 · Cited by 153
New drugs are not enough‑drug repositioning in oncology: An update
Armando, R., Mengual G�mez, D., & Gomez, D. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.4966 · Cited by 90
Wang, W.-L., Shih, Y.-T., Wei, S.-Y., & Chiu, J.-J. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01177-z · Cited by 50
Metadata
- Authors
- Jeong, A., Suazo, K. F., Wood, W. G., Distefano, M. D., & Li, L.
- Venue
- Critical Reviews in Biochemistry and Molecular Biology
- Publisher
- Informa UK Limited
- Published
- 2018-05-02
- Volume
- 53
- Issue
- 3
- Pages
- 279-310
- ISSN
- 0045-6411 (ISSN-L)
- 1040-9238
- 1549-7798
- OpenAlex
- W2800620204
- Cited by
- 146
- References
- 57
- FWCI
- 2.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.